ARTICLE 1Executive Severance Benefits Agreement • March 31st, 2003 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • California
THIRD AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • May 9th, 2016 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Third Amended and Restated Executive Severance Benefits Agreement (the “Agreement”) is entered into this 13th day of April, 2016 (the “Effective Date”), between Daniel N. Swisher, Jr. (“Executive”) and Sunesis Pharmaceuticals, Inc. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • May 15th, 2007 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Severance Benefits Agreement (the “Agreement”) is entered into this 14th day of May, 2007 (the “Effective Date”), between Valerie L. Pierce (“Executive”) and Sunesis Pharmaceuticals, Inc. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.
AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • November 9th, 2007 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • California
This AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into as of this 14th day of September, 2007 (the “Effective Date”), between LEWIS J. STUART (“Executive”) and CV THERAPEUTICS, INC. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • November 27th, 2007 • Novacea Inc • Pharmaceutical preparations • California
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into this 26th day of November, 2007 (the “Effective Date”), between EDWARD F. SCHNIPPER, M.D. (“Executive”) and NOVACEA, INC. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • May 26th, 2006 • Sbe Inc • Computer communications equipment • California
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • February 5th, 2010 • Symmetricom Inc • Telephone & telegraph apparatus • California
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into this day of , (the “Effective Date”), between (“Executive”) and SYMMETRICOM, INC. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • December 22nd, 2020 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into this ___ day of _____________, ____ (the “Effective Date”) between (“Executive”) and SUNESIS PHARMACEUTICALS, INC. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.
Executive Severance Benefits AgreementExecutive Severance Benefits Agreement • February 26th, 2019 • Five Prime Therapeutics Inc • Pharmaceutical preparations • California
This Executive Severance Benefits Agreement (this “Agreement”), effective as of November 26, 2018 (the “Effective Date”), is between David Smith (“Executive”) and Five Prime Therapeutics, Inc. (“FivePrime”). This Agreement is intended to provide Executive with certain compensation and benefits in the event that Executive is subject to certain qualifying terminations of employment. Certain capitalized terms used in this Agreement are defined in Article 6.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • January 22nd, 2014 • Five Prime Therapeutics Inc • Pharmaceutical preparations • California
release the Company from its obligation to indemnify me pursuant to the Company’s indemnification obligation pursuant to written agreement or applicable law.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • March 26th, 2013 • Guitar Center Holdings, Inc. • Retail-radio, tv & consumer electronics stores • Delaware
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is made and entered into effective as of April 28, 2010 (the “Commencement Date”), between Guitar Center, Inc., a Delaware corporation (the “Company”), and Eugene J. Joly (the “Executive”).
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • August 9th, 2006 • Guitar Center Inc • Retail-radio, tv & consumer electronics stores • California
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is made and entered into effective as of April 29, 2006 (the “Commencement Date”), between [Guitar Center, Inc.][Musician’s Friend, Inc.][Guitar Center Stores, Inc.], a Delaware corporation (the “Company”), and (the “Executive”).
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • February 21st, 2019 • Mellanox Technologies, Ltd. • Semiconductors & related devices • California
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into effective as of the Executive’s first date of employment with Mellanox Technologies, Inc. (the “Effective Date”), between Doug Ahrens (“Executive”) and MELLANOX TECHNOLOGIES, LTD. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • March 17th, 2008 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
This EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into this fourth day of August, 2005 (the “Effective Date”), between ROBERT MCDOWELL, PH.D. (“Executive”) and SUNESIS PHARMACEUTICALS, INC. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 6.
AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • August 1st, 2019 • Mellanox Technologies, Ltd. • Semiconductors & related devices
This AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into effective as of this 20th day of June, 2019 (the “Effective Date”), between EYAL WALDMAN (“Executive”) and MELLANOX TECHNOLOGIES, LTD. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events and supersedes in its entirety that certain Amended and Restated Executive Severance Benefits Agreement entered into by and between Executive and the Company dated as of December 19, 2008 (the “Prior Agreement”). Certain capitalized terms used in this Agreement are defined in Article 5.
Amendment No. 1 to the Executive Severance Benefits AgreementExecutive Severance Benefits Agreement • June 14th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 1 to the Executive Severance Benefits Agreement (this “Amendment”), effective May 8, 2013 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”), and Francis Sarena, an individual (“Executive”).
Amendment No. 1 to the Executive Severance Benefits AgreementExecutive Severance Benefits Agreement • February 24th, 2017 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 1 to the Executive Severance Benefits Agreement (this “Amendment”), effective January 21, 2016 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”), and Robert Sikorski, an individual (“Executive”).
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • September 19th, 2023 • Eastern Bankshares, Inc. • Savings institution, federally chartered • Massachusetts
This Executive Severance Benefits Agreement (this “Agreement”) is made this 19th day of September 2023, by and between Denis Sheahan (the “Executive”) and Eastern Bank (“Bank”). Each of Bank and the Executive is sometimes referred to in this Agreement as a “Party” and collectively as the “Parties”.
Amendment No. 1 to the Executive Severance Benefits AgreementExecutive Severance Benefits Agreement • January 22nd, 2014 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 1 to the Executive Severance Benefits Agreement (this “Amendment”), effective January 16, 2014 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”), and Marc Belsky, an individual (“Executive”).
ARTICLE 1Executive Severance Benefits Agreement • March 27th, 2001 • Aviron • Biological products, (no disgnostic substances) • California
ARTICLE 1Executive Severance Benefits Agreement • December 10th, 2001 • Aviron • Biological products, (no disgnostic substances) • California
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • February 13th, 2009 • Monogram Biosciences, Inc. • In vitro & in vivo diagnostic substances • California
THIS EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “AGREEMENT”) is entered into this ___ day of _____________, _____ (the “Effective Date”), between _____________________ (“EXECUTIVE”) and Monogram Biosciences Inc. (the “COMPANY”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.
AMENDMENT TO EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • February 26th, 1999 • Oscar Acquisition Corp • Services-computer programming services
Amendment No. 1 to the Executive Severance Benefits AgreementExecutive Severance Benefits Agreement • June 14th, 2013 • Five Prime Therapeutics Inc • Pharmaceutical preparations
This Amendment No. 1 to the Executive Severance Benefits Agreement (this “Amendment”), effective December 5, 2012 (the “Amendment Effective Date”), is made and entered into by and between Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”), and Aron Knickerbocker, an individual (“Executive”).
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • November 14th, 2006 • Mellanox Technologies, Ltd. • Semiconductors & related devices • California
This Executive Severance Benefits Agreement (the “Agreement”) is entered into this ___day of , 2006 (the “Effective Date”), between [•] (“Executive”) and Mellanox Technologies, Ltd. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.
AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • August 3rd, 2018 • Mellanox Technologies, Ltd. • Semiconductors & related devices
This AMENDED AND RESTATED EXECUTIVE SEVERANCE BENEFITS AGREEMENT (the “Agreement”) is entered into effective as of this [ ˜ ] day of [ ˜ ], 2018 (the “Effective Date”), between [ ˜ ] (“Executive”) and MELLANOX TECHNOLOGIES, LTD. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events and supersedes in its entirety any prior Executive Severance Benefits Agreement entered into by and between Executive and the Company (the “Prior Agreement”). Certain capitalized terms used in this Agreement are defined in Article 5.
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • November 14th, 2006 • Mellanox Technologies, Ltd. • Semiconductors & related devices
This Executive Severance Benefits Agreement (the “Agreement”) is entered into this ___day of , 2006 (the “Effective Date”), between [•] (“Executive”) and Mellanox Technologies, Ltd. (the “Company”). This Agreement is intended to provide Executive with the compensation and benefits described herein upon the occurrence of specific events. Certain capitalized terms used in this Agreement are defined in Article 5.
EXECUTIVE SEVERANCE BENEFITS AGREEMENT FOR EXECUTIVE VICE PRESIDENTS AND SENIOR VICE PRESIDENTS1Executive Severance Benefits Agreement • December 9th, 2013 • American Airlines Inc • Air transportation, scheduled • New York
SUNESIS PHARMACEUTICALS, INC. AMENDMENT TO EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • March 13th, 2013 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS AMENDMENT TO EXECUTIVE SEVERANCE BENEFITS AGREEMENT (“Amendment”) is made as of October 24, 2012, by and between SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ADAM R. CRAIG (“Executive”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Severance Agreement (as defined below).
EXECUTIVE SEVERANCE BENEFITS AGREEMENTExecutive Severance Benefits Agreement • May 4th, 2020 • Eastern Bankshares, Inc. • Savings institution, federally chartered • Massachusetts
This Executive Severance Benefits Agreement (“Agreement”) is made this day of August 2006, by and between Robert F. Rivers (“Executive”) and Eastern Bank (“Eastern” or the “Bank”) (Executive and Eastern are collectively referred to herein as the “Parties”).
